首页> 美国卫生研究院文献>Carcinogenesis >Integrated multiomic predictors for ovarian cancer survival
【2h】

Integrated multiomic predictors for ovarian cancer survival

机译:卵巢癌生存的综合性多组学预测因子

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Increasingly affordable high-throughput molecular profiling technologies have made feasible the measurement of omics-wide interindividual variations for the purposes of predicting cancer prognosis. While multiple types of genetic, epigenetic and expression changes have been implicated in ovarian cancer, existing prognostic biomarker strategies are constrained to analyzing a single class of molecular variations. The extra predictive power afforded by the integration of multiple omics types remains largely unexplored. In this study, we performed integrative analysis on tumor-based exome-, transcriptome- and methylome-wide molecular profiles from The Cancer Genome Atlas (TCGA) for variations in cancer-relevant genes to construct robust, cross-validated multiomic predictors for ovarian cancer survival. These integrated polygenic survival scores (PSSs) were able to predict 5-year overall (OS) and progression-free survival in the Caucasian subsample with high accuracy (AUROC = 0.87 and 0.81, respectively). These findings suggest that the PSSs are able to predict long-term OS in TCGA patients with accuracy beyond that of previously proposed protein-based biomarker strategies. Our findings reveal the promise of an integrated omics-based approach in enhancing existing prognostic strategies. Future investigations should be aimed toward prospective external validation, strategies for standardizing application and the integration of germline variants.
机译:越来越多的负担得起的高通量分子谱分析技术已使全基因组个体间变异的测量成为可能,以预测癌症的预后。尽管卵巢癌涉及多种类型的遗传,表观遗传和表达变化,但现有的预后生物标志物策略仅限于分析一类分子变异。多种组学类型的集成所提供的额外预测能力在很大程度上尚未得到开发。在这项研究中,我们对来自癌症基因组图谱(TCGA)的基于肿瘤的外显子组,转录组和甲基组全分子谱进行了综合分析,以分析与癌症相关的基因的变异,从而构建了强有力的,交叉验证的卵巢癌多组学预测因子生存。这些综合的多基因生存评分(PSSs)能够以高准确度预测白种人子样本的5年总体生存率(OS)和无进展生存率(AUROC分别为0.87和0.81)。这些发现表明,PSS能够预测TCGA患者的长期OS,其准确性超出了先前提出的基于蛋白质的生物标记策略。我们的发现揭示了基于组学方法的综合方法有望增强现有的预后策略。未来的研究应针对预期的外部验证,标准化应用策略和种系变异的整合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号